F9-3 Percutaneous acetic acid injection (PAI) for small hepatocellular carcinoma (HCC) in comparison with percutaneous ethanol injection (PEI)

Ohnishi, Kohei; Yoshioka, Hayato; Yamagishi, Fuminori; Itoh, Shigeo; Fujiwara, Kisako

doi:10.1016/0928-4346(95)90256-7

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acetic acid is characterized by better tissue diffusion than ethanol. Fewer treatment sessions and smaller volume of acetic acid per session can achieve the same degree of tumor ablation as ethanol 23 Acetic acid has a higher diffusion capacity; it is easily available and cheap. Additionally, percutaneous acetic acid injection (PAI), also helps in infiltrating the tumor septae, and capsule.…”

Section: Chemical Ablationmentioning

confidence: 99%

See 1 more Smart Citation

Interventional Radiology in Hepatocellular Carcinoma: Current Status and Looking Ahead

Aravind,

Mukund

2022

Indographics

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and its incidence is on the rise. Although transplantation and surgical resection remain the definitive curative treatment options, only a minority of patients are eligible for these owing to advanced stage of disease at diagnosis. Over the last two decades, various interventional radiology (IR) therapies such as ablative and transarterial therapies, have come to the forefront of HCC management. IR also plays a role in preoperative management of HCC patients with procedures such as portal vein embolization. The recently updated Barcelona Clinic Liver Cancer (BCLC) staging system for HCC provides a guideline for choosing the optimum treatment modality for individual patients, with IR playing a central role. This review summarizes the different IR treatment options in HCC, including various ablative therapies, Transarterial Chemoembolization (TACE), Transarterial Radioembolization (TARE), Portal Vein embolization, emphasizing patient selection, procedural considerations and response evaluation.

show abstract

Section: Chemical Ablationmentioning

confidence: 99%

“…Uncommon side effects such as transient hemoglobinuria, fever, segmental hepatic infarction, and metabolic acidosis can occur. 23…”

Section: Chemical Ablationmentioning

confidence: 99%

Interventional Radiology in Hepatocellular Carcinoma: Current Status and Looking Ahead

Aravind,

Mukund

2022

Indographics

View full text Add to dashboard Cite

show abstract

Hepatocellular carcinoma

Falkson¹,

Falkson²,

Garbers³

1998

Cancer Treatment and Research

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) represents approximately 90% of all cases of primary liver cancer, which is the second leading cause of cancer related deaths globally and has an incidence of 850,000 new cases per year. The main risk factors for developing HCC are wellknown and include infection with hepatitis B and C viruses, alcohol intake and ingestion of the fungal metabolite aflatoxin B1. Nonetheless, knowledge is emerging regarding additional risk factors such as non-alcoholic steatohepatitis. Advances in the understanding of the molecular pathogenesis of HCC led to identification of critical driver mutations, however the most prevalent of these are not yet druggable targets. The molecular classification of HCC is not established, and the Barcelona-Clinic-Liver Cancer Classification is the main clinical algorithm for the stratification of patients according to prognosis and treatment allocation. Surveillance programmes enable detection of early-stage tumours that are amenable to curative therapies-resection, liver transplantation or local ablation. At more-developed stages, only chemoembolization (for intermediate HCC) and sorafenib (for advanced HCC) have shown survival benefits. There are major unmet needs in HCC management that might be addressed through discovery of new therapies and their combinations for use in the adjuvant setting and for intermediate and advanced stage disease, biomarkers for therapy stratification, patient-tailored strategies targeting driver mutations and/or activating signalling cascades and validated measurements of quality of life. Recent failures in testing systemic drugs for intermediate and advanced stages have pointed towards a refinement in trial design and defining novel approaches.

show abstract

F9-3 Percutaneous acetic acid injection (PAI) for small hepatocellular carcinoma (HCC) in comparison with percutaneous ethanol injection (PEI)

Cited by 2 publications

References 0 publications

Interventional Radiology in Hepatocellular Carcinoma: Current Status and Looking Ahead

Interventional Radiology in Hepatocellular Carcinoma: Current Status and Looking Ahead

Hepatocellular carcinoma

Contact Info

Product

Resources

About